Publication details

Idarucizumab (Praxbind®) – studie RE-VERSE AD

Title in English Idarucizumab (Praxbind®) – the RE-VERSE AD study
Authors

PENKA Miroslav MICHALCOVÁ Jana ZAVŘELOVÁ Jiřina PRUDKOVÁ Marie BULIKOVÁ Alena

Year of publication 2016
Type Article in Periodical
Magazine / Source Hypertenze & kardiovaskulární prevence
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords thrombin; inhibitor; antidote; idarucizumab; RE-VERSE AD
Description The recent introduction of idarucizumab as specific antidote for dabigatran to clinical practice represents an important progress in safety of antithrombotic therapy. The RE-VERSE AD study confirmed the efficacy and safety of idarucizumab for dabigatran reversal.

You are running an old browser version. We recommend updating your browser to its latest version.

More info